Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
7 drugs in development
By Therapeutic Area
top 4
R&D Momentum
82/100
Pipeline Velocity
56/100
Trial Completion Rate
87/100
Pipeline Concentration
26/100
Pipeline Freshness
9/100
Strategic Signals
Activity
Last 14 days
A Phase II, Single-Center Platform Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy in Patients With Locally Advanced, Resectable HER2-Positive Gastric or Gastroesophageal Junction Cancer
The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia: a Multicenter, Open-label, Single Arm Trial, Investigator Initiated Study
Development and Utilization of a Comprehensive Genetic-Clinical Database
Feasibility of a Self-Hosted Vision-Language Model for Detecting Caregiver Contact and External Support, the Observable Criteria That Define GMFCS Levels, From Multi-View Movement Video in Children Aged 2 to 6 Years With Cerebral Palsy: A Two-Center Diagnostic Accuracy Study
Rebamipide Versus Diquafosol-Cyclosporine for Perioperative Dry Eye Disease in Cataract Surgery: A Randomized Trial
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
Efficacy and Safety of Digital Therapeutics for Improving Shoulder Function After Rotator Cuff Repair: A Prospective, Randomized, Parallel-Group, Evaluator-Blinded Study
A Prospective Phase II Study of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) Combined With Immunotherapy in Patients With Advanced Hepatocellular Carcinoma
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)